Zemcelpro, a cord blood-sourced cell therapy developed by startup ExCellThera, received conditional marketing authorization in Europe as a treatment for blood cancer patients who can’t find a matched donor. It’s the first cell therapy approved in Europe for this group of patients.
The post European Commission Approval Gives Blood Cancer Patients a New Cell Therapy Option appeared first on MedCity News.
